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colonization, chronic inflammation, and progressive tissue 
destruction.[1] Despite the paucity of data regarding BE 
prevalence worldwide, a recent population-based study 
showed that BE is far from being defined a rare disease.[2]
BE represents the outcome of a wide group of etiological 
factors, with patients sharing different clinical manifestations, 
responses to treatment, and clinical outcomes.[3] In daily 
clinical practice, the spectrum of the disease can move 
from mild disease with limited clinical and radiological 
ABSTRACT
Bronchiectasis (BE) is a heterogeneous disease. Similarly, to other chronic airway 
diseases, such as asthma and chronic obstructive pulmonary disease, management 
of BE patients requires a specific and personalized treatment that depends on many 
clinical, functional, and microbiological variables. Therefore, developing phenotyping 
methods that can help clinical and therapeutic choices is of paramount importance. 
Various methodological approaches have been used to personalize patients’ 
management. In this review, we explore the main tools identified so far to classify and 
phenotype BE patients, including the approaches based on BE etiologies, disease 
severity, cluster analysis, and endotyping. We also discuss the strengths and limitations 
of every approach and highlight the similarities and differences between these studies. 
Finally, we review the therapeutic implications and clinical management connected 
with each approach.
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Bronchiectasis (BE) is a chronic disease of the airways 
characterized by irreversible dilation of the bronchi. These 
alterations lead to the impairment of mucociliary clearance 
and the onset of a vicious circle with persistent bacterial 
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impairment to more severe disease with disseminated 
pulmonary involvement, severe functional impairment, 
chronic airways infection by difficult-to-treat pathogens, 
and frequent exacerbations.
Between these two extreme scenarios, a wide range of clinical 
syndromes might exist, implying a tailored management 
approach. So far, there are no specific indications for tailored 
treatment for BE patients.[3] Over the past few years, several 
research groups tried to identify a tool to either stratify or 
cluster BE patients to detect specific groups that might 
respond to different treatments.[4-9] In the recent past, studies 
with a similar aim conducted in other respiratory conditions, 
including chronic obstructive pulmonary disease (COPD) 
and asthma, have led to more personalized medicine 
approaches.[10,11]
The aim of this review is to evaluate the current literature 
using various approaches to classify BE patients, with 
special attention to their clinical aspects and therapeutic 
perspectives.
AN ETIOLOGY‑BASED APPROACH
The most common etiologies of BE include previous 
severe respiratory infections (e.g., bacterial pneumonia 
o r  t u b e r c u l o s i s ) ,  a l l e rg i c  b r o n c h o p u l m o n a r y 
aspergillosis (ABPA), impairment of ciliary clearance 
(e.g., primary ciliary dyskinesia), immunodeficiencies 
(e.g., hypogammaglobulinemia), and other airway diseases, 
such as COPD and severe asthma.[3] However, there are 
many strengths and limitations related to this approach. 
The identification of treatable causes of BE may prevent 
the evolution of the disease, and international guidelines 
recommend to detect them. However, the etiology of BE 
leading to targeted therapy is only identified in a minority 
of cases.[12] This reflects that idiopathic and postinfectious 
etiologies generally account for 50–70% of all cases in many 
case series.[12] There is no agreement on the minimum 
bundle of tests to be performed to identify BE etiology, 
and recommendations of the international guidelines 
are not met in real life.[13] Several etiologies have been 
associated with BE, but the real “cause–effect” relationships 
have been proved only in a few cases. Typical examples 
are the association between BE and nontuberculous 
mycobacteria (NTM) or ABPA where the “chicken-and-the 
egg” story might occur. Both NTM and ABPA might either 
predispose to the development of BE or colonize a BE lung. 
Furthermore, identification of some etiologies of BE, such 
as the “postinfective” one, suffers significant recall bias 
related to the difficulties in collecting information on a low 
respiratory tract infection episode occurred several years 
before. Finally, no good evidence has been published so far 
concerning the causality in the association/overlap between 
BE and obstructive diseases such as asthma and COPD.[14]
According to a recent meta-analysis on the BE etiology, 
the idiopathic etiology was found in an average of 44.8% 
cases, with a high interstudy variability (range: 5–82%) 
depending on geographical and diagnostic differences.[12] 
Apart from idiopathic BE, the other most common etiologies 
were postinfective (29.9%), immunodeficiency (5%), 
COPD (3.9%), and connective tissue disease (3.8%).[12]
All of the latest international guidelines strongly recommend 
a comprehensive diagnostic workup, including a thorough 
medical history and baseline investigations, such as full blood 
count, major immunoglobulin classes, and serological tests 
for Aspergillus species.[3,15] Furthermore, cultures of airway 
secretions are strongly recommended because they can 
detect pathogens, such as NTM.[15] However, according to 
the meta-analysis published by Gao et al., the identification 
of the BE etiologies led to changes in patients’ management 
only in 18% of cases.[12]
In a recent paper, Lonni et al. evaluated the possible 
correlation between BE etiologies and disease severity.[16] 
No significant differences in the etiology of BE were found 
across different levels of disease severity, with the exception 
of a higher prevalence of COPD-related BE and a lower 
prevalence of idiopathic BE in patients with severe disease.
Few studies have evaluated patients’ phenotyping according 
to BE etiology [Table 1].[7-9]
Buscot et al. performed a retrospective, single-center, 
university hospital-based study on 311 BE patients in Nice, 
France.[7] They detected three phenotypes with distinct 
clinical, functional, and microbiological features: idiopathic, 
congenital, and COPD-associated BE [Table 1]. Anwar 
et al. identified two main groups: idiopathic BE and 
postinfection BE, with the latter being significantly younger 
at symptom onset compared to the former group.[8] King 
et al., who collected data from 195 adult BE patients at a 
University Hospital in Melbourne, Australia,[9] based their 
phenotyping on the disease onset. Patients with childhood 
onset, despite the younger age, showed higher disease 
severity and higher number of exacerbations.
A SEVERITY‑BASED APPROACH
Another approach aimed to classify patients with BE 
is based on the degree of disease severity. BE severity, 
ranging from cases without symptoms or exacerbations to 
patients requiring lung transplantation, greatly impacts 
on patients’ management. Two recognized severity 
scores are the BE Severity Index (BSI) and the FACED 
score [Table 2].[17,18] They share some items, including 
age, pulmonary function tests (PFTs) with the forced 
expiratory volume in the in the 1st second (FEV1), presence 
of bacterial colonization, radiological extension, and the 
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Table 1: Studies reporting bronchiectasis phenotyping according to bronchiectasis etiology and disease onset
Buscot et al. 2016[7]
COPD‑associated Predominantly men, associated with tobacco use. Pts are older (median age 73 yrs), have more severe airway 
obstruction at diagnosis and P. aeruginosa is more frequently found in the sputum (65% of cases). Pts have a higher 
proportion of pulmonary hypertension (16% of cases).
Congenital Younger pts at diagnosis (median age 20 yrs), lower rate of smoking (13%). Almost all of them (93%) have potential 
pathogens in their sputum (P. aeruginosa in 57% of cases, H. influenzae in 50%, and S. aureus in 36%). 40% 
underwent lobectomy.
Idiopathic Mostly women, rarely smokers. Pts have better spirometry values at diagnosis and are less likely to carry 
P. aeruginosa (30% of cases).
Anwar et al. 2013[8]
Idiopathic Pts in this group are older at symptoms onset (mean age 42 yrs) and with reduced diagnostic delay compared to 
“post‑infective” etiology (13 yrs).
Post‑infective Pts reporting a history of symptoms onset within 10 yrs of a severe respiratory tract infection, such as pneumonia, 
whooping cough or complicated measles infection. It includes post‑tuberculous BE. Pts in this group are younger 
at symptoms onset (mean age 19 yrs) but with prolonged diagnostic delays (26 yrs). They are more likely to have 
a history of childhood infections, including pneumonia. They are also more likely to have a history of rhinitis and 
lobectomy.
King et al. 2009[9]
Childhood onset Mostly women with longer duration of productive cough; higher prevalence of rhinosinusitis, exacerbations per 
year (mean 3/yr) and presence of crepitations on physical exam. Worse PFTs and radiological alterations. Higher 
proportion of adequate sputum specimens for microbiological analysis and higher incidence of P. aeruginosa.
Adult onset Higher age at diagnosis (mean age 61 yrs) with shorter duration of symptoms. Lower number of exacerbations (mean 
2/yr). Less severe radiological and functional involvement. Lower volume of sputum and higher incidence of no 
growth on sputum specimens.
BE: Bronchiectasis, pts: Patients, yrs: years, COPD: Chronic obstructive pulmonary disease.
Table 2: Bronchiectasis Severity Scores
Bronchiectasis Severity Index (17) FACED score (18)
FEV1% predicted > 80 0 points ≥ 50% 0 points
50‑80 1 point < 50% 2 points
30‑49 2 points
< 30 3 points
Age < 50 years 0 points < 70years 0 points
50‑69 years 2 points ≥ 70years 2 points
70‑79 years 4 points
≥ 80 years 6 points
Chronic bacterial colonization P. aeruginosa 3 points No 0 points
other organisms 1 point Yes, with P. aeruginosa 1 point
None 0 points
Number of lobes with BE ≤ 2 0 points ≤ 2 0 points
> 2 or cystic BE 1 point > 2 1 point
Dyspnea, mMRC score ≤ 3 0 points ≤ 2 0 points
4 2 points > 2 1 point
5 3 points
Body mass index < 18.5 2 points
≥ 18.5 0 points
Hospital admissions in the past 2 years Yes 5 points
No 0 points
Exacerbation frequency in the past 12 months < 3 0 points
≥ 3 2 points
BSI: 0-4 points, low risk of hospitalization and mortality, 5-8 points: moderate risk of hospitalization and mortality, ⩾9 points: high risk of hospitalization and 
mortality. FACED score: low risk 5-year all-cause mortality (0-2 points), moderate risk of mortality (3-4 points), high risk of mortality (5-7 points). FEV1: Forced 
expiratory volume in the 1st second, BE: Bronchiectasis, mMRC scale: Modified Medical Research Council Scale, BSI: Bronchiectasis Severity, yrs: years, COPD: 
Chronic obstructive pulmonary disease.
presence of dyspnea (evaluated through the modified 
Medical Research Council Scale [mMRC]). These 
scoring systems were created to predict patients at high 
risk of mortality, hospitalization, and exacerbations in 
the case of the BSI, or only mortality in the case of the 
FACED score. Recently, Li et al. from China created and 
validated a scoring system for identifying patients at risk of 
exacerbations.[19] Most of the proposed items were similar 
to those by Chalmers et al. and Martínez-García et al., 
including age, dyspnea evaluated through the mMRC 
scale, Pseudomonas aeruginosa colonization, extension 
of radiological involvement, and PFTs impairment. The 
authors also included the presence of prior intensive care 
unit admission.
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Several studies compared the BSI and the FACED 
scores.[20-22] Ellis et al. found that both scoring systems 
had similar predictive power for 5-year mortality, with the 
FACED score showing slightly superior predictive power 
for 15-year mortality.[21] The BSI was also developed to 
predict the risk of hospitalization and exacerbations. 
A recently published study by McDonnell et al. directly 
compared BSI and FACED scores for the assessment of 
clinically relevant disease outcomes across seven European 
cohorts.[22] The study showed that both scores accurately 
predicted mortality, but BSI was superior to FACED in 
predicting multiple outcomes, including hospital admissions, 
exacerbations, quality of life, and lung function decline. 
The ability of predicting not only mortality but also other 
clinically relevant outcomes supports the utility of BSI in 
“real-life” decision-making processes. Patients at high risk 
may benefit from aggressive treatment while those at low-risk 
could receive nonspecialist follow-up or simpler treatment 
regimens. Data to validate this approach are now needed.
While severity scores provide an important piece of 
the puzzle formed by the patient and their disease, 
they do not allow a personalized approach, with, for 
instance, two very different clinical cases characterized 
by similar BSI or FACED scores and different clinical 
management [Table 3].
PHENOTYPING ACCORDING TO CLINICAL AND 
MICROBIOLOGICAL CHARACTERISTICS WITH A 
CLUSTER‑BASED APPROACH
The third approach that has emerged more recently is 
cluster-based analysis.
Cluster analysis refers to a group of multivariate 
mathematical algorithms that broadly perform two 
distinct functions: (1) quantification of similarity between 
individuals within a population on the basis of (multiple) 
specified variables; (2) grouping of individuals into clusters 
such that similarity between members of the same clusters 
is strong, while similarities between members in different 
clusters is weak.[11,23] Furthermore, to validate the primary 
cluster analysis, independent external cohorts are recruited.
In recent years, several phenotypes for asthma and COPD 
have been proposed.[10,11] Two kinds of phenotypes of 
asthmatic patients have been used: clinical (e.g., allergic, 
aspirin-sensitive, and glucocorticoid-resistant asthma[24]) 
and pathophysiological phenotypes (e.g., eosinophilic, 
neutrophilic, mixed inflammatory, and paucigranulocytic 
asthma).[25] These approaches are sometime referred 
to (clinical) phenotyping and endotyping, respectively.
The former category is helpful to clinicians because it can be 
detected through clinical history and physical examination. 
The latter category is important for pharmacologists, 
allowing the development of therapies targeted to the 
pathophysiological mechanisms of the disease. The 
distinction between phenotypes allows the clinician to 
identify the best-individualized treatment.
Focusing on BE, to date, there are three main studies 
describing clinical phenotyping.
Aliberti et al. performed a principal component and 
cluster analyses using data from five European BE 
registries (1145 patients).[4] The authors identified four 
clinical phenotypes mainly based on microbiological 
isolations and respiratory symptoms [Table 4]. These 
groups differ from one another both from a therapeutic and 
prognostic point of view. In the Pseudomonas cluster, more 
than 50% of the patients were exposed to a macrolide, and 
more than one-third were on inhaled antibiotic treatment; 
this cluster also showed higher rates of exacerbations, 
hospitalizations, and mortality rate during the 3-year 
follow-up period. One-third of the patients in the “other 
chronic infection” and “daily sputum” clusters were on 
long-term macrolides, while few patients received inhaled 
antibiotic therapy; these two clusters also shared a similar 
3-year mortality rate and number of hospitalizations at 
1-year follow-up. The “dry BE” cluster showed the best 
outcomes and rarely received antibiotic maintenance 
therapy.
Guan et al. performed a hierarchical cluster analysis on a data 
set of 148 adult Chinese patients with BE.[5] Clusters were 
defined by patient’s age at symptoms’ onset and past clinical 
history [Table 4]. Cluster #2 and, secondly, Cluster #3, 
showed similarities with the Pseudomonas group of the study 
by Aliberti et al. These two clusters showed more extensive 
radiological and functional involvement, which translated 
into a greater severity of disease with more respiratory 
symptoms and worse quality of life. P. aeruginosa colonization 
was common in both groups. Furthermore, similarly to the 
Pseudomonas cluster, these two groups showed high rates of 
macrolide therapy, increased number of BE exacerbations in 
the previous 2 years and increased health-care utilization. 
Guan et al. also described cluster #1, which showed mild 
disease severity and shared some characteristics with the “dry 
BE” group by Aliberti et al. The main feature of this cluster 
was the reduced health-care utilization.
Martínez-García et al. in a recently published multicenter 
study described the results of a cluster analysis involving 
468 patients from six Spanish BE reference centers.[6] The 
most severe cluster of patients described in this cohort is the 
“elderly/severe/exacerbators” phenotype. This group shared 
many characteristics with the Pseudomonas and “daily sputum” 
phenotypes by Aliberti et al. and Clusters 2–3 in the study 
by Guan et al. In fact, patients in this group were the oldest, 
the most symptomatic not only for breathlessness but also for 
purulent sputum production, the most likely to have an active 
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Table 3: Different clinical scenarios with similar Bronchiectasis Severity Index and FACED score
Bronchiectasis Severity Index
CASE 1
Older underweight adult with BE‑COPD overlap syndrome 
and emphysema, no chronic bacterial colonization, 
moderate‑to‑severe dyspnea and functional impairment. No 
frequent exacerbator.
‑ FEV1 40% predicted  2 points
‑ Age 75 yrs  4 points
‑ No chronic bacterial colonization  0 points
‑ 2 lobes with BE  0 points
‑ mMRC score=4  2 points
‑ Body mass index=18  2 points
‑ No hospital admissions in the past 2 yrs  0 points
‑ 2 exacerbations in the past 12 months  0 points
CASE 2
Young adult with idiopathic BE, no functional impairment, chronic P. 
aeruginosa colonization and frequent exacerbator. One hospitalization in the 
prior year due to pneumonia.
‑ FEV1 82% predicted  0 points
‑ Age 40 yrs  0 points
‑ Chronic P. aeruginosa colonization  3 points
‑ 2 lobes with BE  0 points
‑ mMRC score=1  0 points
‑ Body mass index=21  0 points
‑ 1 hospital admission in the past 2 yrs  5 points
‑ 3 exacerbations in the past 12 months  2 points
Total score 10 Total score 10
FACED score
CASE 3
Same as Case 1.
‑ FEV1 40% predicted  2 points
‑ Age 75 yrs  2 points
‑ No chronic bacterial colonization  0 points
‑ 2 lobes with BE  0 points
‑ mMRC score=4  1 point
CASE 4
Young adult with post‑infective BE and immunodeficiency, moderate dyspnea, 
radiological and functional impairment. Chronic P. aeruginosa colonization.
‑ FEV1 50% predicted  2 points
‑ Age 40 yrs  0 points
‑ Chronic P. aeruginosa colonization  1 point
‑ 3 lobes with BE  1 points
‑ mMRC score=3  1 point
Total score 5 Total score 5
BE: Bronchiectasis, yrs: years, COPD: Chronic obstructive pulmonary disease, FEV1: Forced expiratory volume in the 1
st second, mMRC scale: Modified Medical 
Research Council Scale.
or prior smoking habit and to have COPD as comorbidity. 
Furthermore, this cluster showed a high prevalence of 
P. aeruginosa and Haemophilus influenzae colonization. 
Chronic treatment with macrolides and inhaled antibiotics 
were used in 34% and 46% of cases, respectively. This group 
showed the worst outcomes, including a high number of 
exacerbations in the prior year and an increased mortality 
for respiratory causes. Martínez-García et al. also described a 
phenotype defined as “elderly/severe/non-exacerbators” that, 
differently from all the phenotypes described in the other 
studies, was characterized by a high mortality rate, but mainly 
due to non-respiratory causes (cardiovascular diseases and 
neoplasms). Interestingly, these patients showed relatively 
low chronic colonization with H. influenzae and P. aeruginosa, 
low number of exacerbations in the prior year, and low use 
of chronic macrolides and inhaled antibiotics. Probably, the 
poor outcomes in this cluster were mainly associated with 
comorbidities and not with BE itself.
The phenotypes presented so far are very useful from a clinical 
point of view; however, their usefulness in understanding the 
biological mechanisms and pathophysiology of the disease 
is less clear and further studies are required.
As observed by the previously described studies, some 
phenotypes may present similar characteristics. This is 
the case for patients in the BE-COPD overlap syndrome 
group by Buscot et al., the Pseudomonas and “daily 
sputum” phenotypes by Aliberti et al., Cluster #3 by Guan 
et al., and the “elderly/severe/exacerbators” phenotype by 
Martínez-García et al.[4-7] In particular, BE patients with 
COPD are usually elderly, very symptomatic subjects with 
multiple comorbidities, and severe functional impairment.
The differences and similarities between the proposed 
phenotypes reflect the heterogeneity of patients worldwide 
and the need to individualize clustering at local and national 
level.
ENDOTYPING OF BRONCHIECTASIS
In the era of targeted therapies in asthma, certain endotypes 
have emerged, including high and low eosinophils and 
periostin groups.[26,27] The characterization of BE endotypes 
could include the evaluation of cellular and soluble factors. 
A recent study by Dente et al. showed higher levels of 
neutrophilic bronchial inflammation in BE patients with 
bacterial colonization, especially with P. aeruginosa and 
elevated BSI.[28] Higher levels of free neutrophil elastase 
activity, myeloperoxidase activity, and interleukin (IL)-1 β 
were also found by Aliberti et al. in the “Pseudomonas” 
and “other chronic infection” clusters, confirming the high 
levels of neutrophil inflammatory markers in patients with 
bacterial colonization.[4]
Some soluble inflammatory markers and, particularly a 
deregulated cytokine network, including IL-8, tumor necrosis 
factor-alpha, and neutrophil elastase are also plausible 
candidates in BE pathogenesis and, thus, potentially useful 
in endotyping.[29]
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These findings suggest that further multicenter studies 
on BE phenotyping-endotyping are required to better 
understand both the pathogenesis of the disease and possible 
therapeutic targets.
This approach has already lead to new therapeutic advances 
in asthma.[30]
In BE patients, Wells et al. have recently demonstrated 
“blocking antibodies” that protect P. aeruginosa from 
complement-mediated killing in a very severe subpopulation 
with P. aeruginosa infection.[31] This abnormality of humoral 
response appears to be characterized by excess production 
of O-antigen-specific IgG2 antibodies and patients with this 
“endotype” have more marked disease severity. This form of 
endotyping may allow us to tailor-specific treatments beyond 
that suggested by the clinical phenotyping alone.
THERAPEUTIC IMPLICATIONS AND CLINICAL 
MANAGEMENT
BE patients grouping on the basis of clinical, microbiological, 
and etiological criteria have implications for the prognosis 
and the therapeutic management of the disease. Patients 
may require individualized treatments based on clinical 
phenotypes.
On the one hand, phenotypes such as “dry BE” in the study 
by Aliberti et al.[4] and patients not colonized by pathogenic 
bacteria, with few respiratory symptoms and low severity of 
Table 4: Studies reporting bronchiectasis phenotyping according to clinical and microbiological characteristics with 
a cluster‑based approach
Aliberti et al. 2016[4]
Cluster 1 ‑ “Pseudomonas” Presence of respiratory symptoms (mainly chronic cough, hemoptysis, and dyspnea) and extensive 
radiological impairment. More severe functional alterations involving PFTs and performance status, 
with increased need for LTOT and worse quality of life. Increased activation of the inflammatory system 
during stable state. All these factors lead to a higher severity and to a more rapid progression of the 
disease, which ultimately translates into an increased number of exacerbations and hospitalizations and 
a higher 3‑year mortality. Pts in this group show more often a post‑infectious etiology.
Cluster 2 ‑ “Other chronic 
infection”
Chronic infection with bacteria other than P. aeruginosa.
Cluster 3 ‑ “Daily sputum” Presence of daily sputum production even in absence of bacterial colonization. These pts are more often 
smokers or ex‑smokers. Pts in this group show more often a COPD‑related etiology.
Cluster 4 ‑ “Dry bronchiectasis” Lower disease severity, with the lowest level of inflammatory biomarkers, the least severe radiological 
and less functional impairment, as well as reduced frequency of respiratory symptoms (in particular, 
absence of daily sputum production). None of these pts have chronic respiratory infections.
Guan et al. 2016[5]
Cluster 1 Younger patients (mean age 40 yrs) with shorter time since symptoms onset, with predominantly mild 
and idiopathic BE, and with minor healthcare resource use. Pts have minimal functional and radiological 
alterations and only mildly impaired quality of life. Most patients show no colonization with pathogenic 
bacteria (80%), and low risk of BE exacerbations.
Cluster 2 Young pts (mean age 41 yrs) with the longest duration of symptoms. Post‑infectious etiology 
predominates. Pts have greater disease severity, with more extensive radiological impairment, poorer 
lung function, higher rate of airway P. aeruginosa colonisation (59%), and frequent health care resource 
use. This cluster comprises the highest number of pts with cystic BE (96%) and atelectasis (55%). 
6‑minute walk distance is the lowest among all clusters, accompanied by low quality of life.
Cluster 3 Elderly pts with shorter duration of symptoms and mostly idiopathic BE. This cluster presents the most 
severe form of BE both radiologically and functionally. Most pts have P. aeruginosa colonization (63%). 
A considerable number of pts have cystic BE (94%), emphysema (44%), pulmonary cavities (75%) and 
bilateral BE (100%). Pts in this group have the lowest quality of life and the greatest risk of experiencing 
pulmonary exacerbations. The use of healthcare resources is frequent.
Cluster 4 Elderly pts with modest time since symptoms onset and moderate disease severity. A few patients have 
P. aeruginosa colonization (17%). This group shows modest use of healthcare resources without quality 
of life impairment.
Martínez‑García et al. 2016[6]
Young/mild phenotype Young women with low BMI, mild disease and no frequent exacerbators. Absence of airflow obstruction. 
Main BE etiologies are: genetic/immune deficiency, post‑infectious or idiopathic. Low rate of 
non‑respiratory comorbidities and chronic bronchial infections.
Elderly/mild phenotype Elderly overweight women with mild disease and no frequent exacerbators. Presence of mild airflow 
obstruction. Main BE etiologies: idiopathic, post‑infectious or asthma. Low rate of non‑respiratory 
comorbidities and chronic bronchial infections.
Elderly/severe/exacerbator Elderly men with moderate‑severe disease, high prevalence of chronic bronchial infection, severe flow 
obstruction, and frequent exacerbations. Main BE etiologies: post‑infectious and COPD‑associated. Low 
rate of non‑respiratory comorbidities.
Elderly/severe/non‑exacerbator 
phenotype
Elderly pts with moderate‑severe disease, severe flow obstruction, low number of exacerbations and 
moderate chronic bronchial infection rate. Main etiologies: post‑infectious and idiopathic. High rate of 
non‑respiratory comorbidities (cardiovascular and neoplasms).
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the disease, do not usually require a close follow-up. Those 
patients after an initial assessment with general therapeutic 
indications (e.g., airway clearance techniques, prevention 
of exacerbations/respiratory infections, and bronchodilation 
if indicated) may be followed up by the general practitioner. 
Some data suggest that up to 30% of these patients may 
acquire P. aeruginosa, so ongoing microbiological surveillance, 
albeit at a low frequency, may be helpful.[32]
On the other hand, patients with chronic infections, 
particularly those with P. aeruginosa, require closer 
follow-up; in those cases, monitoring of sputum cultures, 
both during exacerbations and stable state, becomes of 
primary importance. These patients are candidates for 
targeted therapy, using inhalational antibiotics, for bacterial 
eradication or reduction of bacterial load.
Recently, a single-center retrospective study on the real-life 
use of nebulized antibiotics aimed to characterize the 
clinical phenotype of patients that most benefit from 
such treatment.[33] BE patients with a greater number of 
exacerbations, a lower lung function, a greater presence of 
nodules and cysts on computed tomography scan, and higher 
BSI score seemed to represent a sort of “higher risk” cluster 
of patients that showed the best outcomes after aerosolized 
antibiotics.
Other particular BE phenotypes may require specific 
therapeutic approaches. As an example, COPD-associated 
BE may require counseling for smoking cessation and 
personalized rehabilitation programs. Such patients may 
also be the ones, in whom targeted screening for alpha-1 
antitrypsin deficiency provides a better yield than other 
etiologies.
FUTURE PROSPECTIVES
Although much progress has been achieved recently in 
characterizing BE both from a prognostic and clinical point 
of view, many advances are still needed in the therapeutic 
field. A better knowledge of the BE etiology, with specific 
reference to treatable causes,[3] the increasingly widespread 
use of long-term macrolide therapy,[34-36] as well as a greater 
attention to the prevention of BE exacerbations, and to the 
role of the respiratory therapists have definitely improved 
clinical practice. However, the issue of airways bacterial 
colonization, which seems to be one of the most important 
factors in the severity of the disease, should be adequately 
addressed, particularly in terms of pulmonary targeted 
antimicrobial therapy. Both nebulized and dry powder inhaled 
antibiotics are available for use in cystic fibrosis.[37] To date, 
the available studies mainly focused on P. aeruginosa chronic 
infection, reported worse outcomes, with bacterial eradication 
only in a few cases.[38-40] Furthermore, nebulized antibiotics 
may be associated with side effects (e.g., five times increase 
in bronchospasm reported with inhaled aminoglycosides 
compared to placebo).[41] Therefore, better selection of the 
candidates for inhaled antibiotics, as previously described, as 
well as new molecules or better formulations of the available 
ones could improve patients’ outcomes.
Finally, in regard to phenotyping, future studies should aim 
to assess the applicability in clinical practice of the previously 
described clusters and their power to predict differential 
responses to therapy, to inform on the design of future 
randomized control trials.
CONCLUSIONS
The need of personalizing the management of BE patients 
has been internationally recognized as a research priority 
in the field.[42] The elements that seem to better define 
the severity of BE phenotypes are the presence of chronic 
bronchial infections, primarily with P. aeruginosa, secondly, 
with other bacteria, and the presence of chronic respiratory 
symptoms. The evaluation of the etiology of BE suffers 
from several limitations, and the need of collecting data at 
a multi-country level seems to play a secondary role, with 
the only exception of COPD-associated BE.[43]
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